Together, the CXCR4/CXCL12 axis promotes drug resistance in the tumour primarily in a twofold manner: (1) direct tumour cell survival mechanisms and enrichment of resistant CSC populations, and (2) modifying the TME. This evidence concerns the gene CXCR4 and neoplasm.